Trial · NCT03280550
Results by group138
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 138
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Nasal Polyp Score (NPS) at Week 24 | Placebo | 0.06 | 95% Confidence Interval -0.27 to 0.38 | Score on a scale | |
| Change From Baseline in Nasal Polyp Score (NPS) at Week 24 | Omalizumab | -1.08 | 95% Confidence Interval -1.40 to -0.77 | Score on a scale | |
| Change From Baseline in Average Daily Nasal Congestion Score (NCS) at Week 24 | Placebo | -0.35 | 95% Confidence Interval -0.56 to -0.13 | Score on a scale | |
| Change From Baseline in Average Daily Nasal Congestion Score (NCS) at Week 24 | Omalizumab | -0.89 | 95% Confidence Interval -1.10 to -0.69 | Score on a scale | |
| Change From Baseline in Average Daily Sense of Smell Score at Week 24 | Placebo | -0.23 | 95% Confidence Interval -0.42 to -0.04 | Score on a scale | |
| Change From Baseline in Average Daily Sense of Smell Score at Week 24 | Omalizumab | -0.56 | 95% Confidence Interval -0.74 to -0.38 | Score on a scale | |
| Change From Baseline in Average Daily Posterior Rhinorrhea Score at Week 24 | Placebo | -0.16 | 95% Confidence Interval -0.36 to 0.04 | Score on a scale | |
| Change From Baseline in Average Daily Posterior Rhinorrhea Score at Week 24 | Omalizumab | -0.72 | 95% Confidence Interval -0.91 to -0.53 | Score on a scale | |
| Change From Baseline in Nasal Polyp Score (NPS) at Week 16 | Placebo | 0.03 | 95% Confidence Interval -0.27 to 0.33 | Score on a scale | |
| Change From Baseline in Nasal Polyp Score (NPS) at Week 16 | Omalizumab | -0.98 | 95% Confidence Interval -1.27 to -0.70 | Score on a scale | |
| Change From Baseline in Average Daily Nasal Congestion Score (NCS) at Week 16 | Placebo | -0.32 | 95% Confidence Interval -0.51 to -0.13 | Score on a scale | |
| Change From Baseline in Average Daily Nasal Congestion Score (NCS) at Week 16 | Omalizumab | -0.89 | 95% Confidence Interval -1.07 to -0.71 | Score on a scale | |
| Change From Baseline in Participant Reported Health-Related Quality of Life (HRQoL) as Assessed by the Total Sino-Nasal Outcome Test (SNOT)-22 Questionnaire at Week 24 | Placebo | -8.58 | 95% Confidence Interval -12.71 to -4.46 | Score on a scale | |
| Change From Baseline in Participant Reported Health-Related Quality of Life (HRQoL) as Assessed by the Total Sino-Nasal Outcome Test (SNOT)-22 Questionnaire at Week 24 | Omalizumab | -24.70 | 95% Confidence Interval -28.67 to -20.73 | Score on a scale | |
| Change From Baseline in Average Daily Anterior Rhinorrhea Score at Week 24 | Placebo | -0.34 | 95% Confidence Interval -0.54 to -0.15 | Score on a scale | |
| Change From Baseline in Average Daily Anterior Rhinorrhea Score at Week 24 | Omalizumab | -0.77 | 95% Confidence Interval -0.96 to -0.58 | Score on a scale | |
| Number of Participants Requiring Rescue Medication (Systemic Corticosteroids for ≥3 Consecutive Days) Through Week 24 | Placebo | 3 | Participants | ||
| Number of Participants Requiring Rescue Medication (Systemic Corticosteroids for ≥3 Consecutive Days) Through Week 24 | Omalizumab | 2 | Participants | ||
| Number of Participants Having Had Surgery for Nasal Polyps Through Week 24 | Placebo | 1 | Participants | ||
| Number of Participants Having Had Surgery for Nasal Polyps Through Week 24 | Omalizumab | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03280550/results